Litigation Details for Pfizer Inc. v. Aurobindo Pharma Limited (D. Del. 2024)

Pfizer Inc. v. Aurobindo Pharma Limited (D. Del. 2024)

Docket		Date Filed	2024-05-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	11,083,724
Link to Docket	External link to docket

Details for Pfizer Inc. v. Aurobindo Pharma Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-23				External link to document

Last updated: July 26, 2026

izer Inc. v. Aurobindo Pharma Limited (1:24-cv-00622) Litigation Summary and Patent Infringement Risk Analysis

Pfizer Inc. has asserted patent infringement in an ANDA-related dispute against Aurobindo Pharma Limited under case number 1:24-cv-00622. The matter is filed as a U.S. federal litigation proceeding (District of New Jersey), positioning Pfizer to block or delay U.S. generic entry tied to Aurobindo’s FDA submission and associated Orange Book-listed patents for the asserted Pfizer product.

What patents are at issue in Pfizer v. Aurobindo (1:24-cv-00622)?

This litigation is structured as a patent infringement action in the Hatch-Waxman framework, where Pfizer typically pleads infringement of Orange Book-listed U.S. patents associated with a specific Pfizer reference drug and seeks injunctive relief and damages tied to Aurobindo’s ANDA. The controlling factual record for a complete, accurate “which patents, which claims, which product, which Orange Book listings” answer is the docket filings (complaint, infringement contentions, and claim chart support).

Because the necessary docket text (complaint/relief requested and asserted patent list) is not provided in the available prompt record, a complete and accurate identification of the asserted patents, their numbers, and the specific asserted claims cannot be produced.

How the case typically frames claim construction and infringement allegations

In ANDA Paragraph IV litigation, Pfizer’s infringement case generally includes:

• Identification of asserted U.S. patents listed for the reference listed drug (RLD) in FDA’s Orange Book.
• Mapping of the accused Aurobindo ANDA product (and its proposed label) to claim elements.
• A request for a permanent injunction barring FDA approval or launch until patent expiry, plus damages for any commercial manufacture, use, offer to sell, or sale.

What to look for in the docket to confirm the patent list

A full patent slate normally appears in:

• The complaint (asserted patents and infringement theories).
• Early scheduling orders (claim construction and Markman sequence).
• Pfizer’s infringement contentions.
• Aurobindo’s invalidity and non-infringement contentions.
• Any motion practice (Rule 12, summary judgment, or claim construction rulings).

What is the case status and procedural posture in 1:24-cv-00622?

The prompt provides only the case number and parties (Pfizer Inc. v. Aurobindo Pharma Limited | 1:24-cv-00622). Without the docket chronology, filings, or court orders, an exact status call (for example, whether the matter is at the pleading stage, undergoing claim construction, or post-dispositive) cannot be made accurately.

Typical post-filing milestones in ANDA patent cases

If the matter follows standard Hatch-Waxman procedure, the docket usually includes:

• Answer and defenses (including invalidity, non-infringement, unenforceability, and statutory defenses).
• Claim construction (Markman) briefing and hearing.
• Discovery scope orders (often limited in ANDA cases).
• Dispositive motions (non-infringement, invalidity, anticipation, obviousness, and §112 arguments).
• Trial or resolution via settlement, consent judgment, or dismissal.

What Paragraph IV settlement or launch timelines are most relevant for Aurobindo’s generic entry risk?

Paragraph IV litigation is designed to determine the timing of generic market entry through:

• Potential 30-month stay (triggered by a timely Paragraph IV notice and FDA acceptance of an ANDA).
• Patent-by-patent injunction exposure and settlement-driven “carve-out” entry dates.
• Possible partial settlements for subsets of Orange Book patents.

A precise exclusivity and launch window for this case requires:

• The RLD name, the asserted patents and their expiry dates,
• The date of the Paragraph IV notice to the NDA holder,
• The 30-month stay trigger and any court decisions affecting it (for example, invalidity rulings or preliminary injunction findings).

Those facts are not present in the prompt record, so a quantified entry-risk timeline cannot be produced.

How strong is Pfizer’s patent estate versus Aurobindo’s generic non-infringement and invalidity defenses?

Strength assessment depends on:

• The patents asserted (composition, method-of-use, formulation, or manufacturing),
• The claim breadth and remaining life,
• Prior prosecution history and reexamination/certification,
• Prior art landscape and expert support for obviousness/anticipation,
• Whether Aurobindo’s proposed formulation or dosage form design avoids claim coverage.

Without the asserted patent numbers and claim language, the strength cannot be evaluated in a way that is both complete and accurate.

Common defense angles Aurobindo uses in ANDA cases

In Hatch-Waxman cases against multinational brand owners, generic challengers commonly argue:

• Non-infringement: the ANDA product does not meet all claim elements.
• Invalidity:
  • Lack of novelty (anticipation).
  • Obviousness (KSR rationale and combination teachings).
  • Written description or enablement (§112).
  • Indefiniteness (§112(b)).
• Unenforceability: inequitable conduct or failure to comply with disclosure obligations (less common but pleaded in some matters).

Common brand-side angles Pfizer uses

Pfizer typically counters by:

• Construing claims broadly enough to read on the ANDA product attributes.
• Relying on expert evidence and testing, including comparative dissolution/PK bridging where relevant.
• Attacking obviousness with secondary considerations and non-analogous prior art.

What is the Orange Book status of the asserted Pfizer patents in this dispute?

Orange Book status (patent listing type and expiration) is the backbone for:

• The 30-month stay analysis,
• The injunction scope,
• Settlement entry dates,
• Liability allocation (which patents control).

A complete Orange Book table requires the RLD and Orange Book listing details. The prompt does not include the asserted product identity or the Orange Book listing entries, so an accurate status table cannot be produced.

How does this case compare with other Pfizer v. generic ANDA litigations (Aurobindo or peers)?

Antenna-style comparisons require:

• The same Pfizer product family, or
• Comparable patent classes (for example, method-of-use vs. formulation vs. polymorph),
• Similar infringement theories and claim types.

The prompt record does not include the drug or patent class. Without that, any “comparison” would be speculative.

What generic entry risks exist if Pfizer obtains an injunction or if claims are narrowed?

Generic launch risk in ANDA litigation depends on:

• Whether the asserted patents are foundational composition/method patents or narrower formulation/manufacturing patents,
• Whether the court narrows claim construction,
• Whether Aurobindo can design around non-infringing features while still meeting FDA approval needs.

A detailed risk assessment requires:

• The asserted claim elements and whether the ANDA product can be modified,
• Remaining patent life and whether any patents survive invalidity.

None of those inputs are in the prompt record.

Key Takeaways

• The case is an ANDA-related patent infringement dispute: Pfizer Inc. v. Aurobindo Pharma Limited, 1:24-cv-00622.
• A fully accurate litigation summary on asserted patent numbers, Orange Book listings, procedural status, and quantified generic entry timelines cannot be generated from the provided record alone.
• The business relevance in such matters is driven by asserted patent scope (composition/method/formulation), remaining term, and claim construction outcomes, which must be confirmed in the docket’s complaint and subsequent filings.

FAQs

1. Does 1:24-cv-00622 involve a Paragraph IV notice and a 30-month stay?
2. Which specific Pfizer Orange Book patents did Pfizer assert in the complaint?
3. What court deadlines apply to claim construction and expert discovery in 1:24-cv-00622?
4. What settlement structure is most likely in Pfizer vs. Aurobindo ANDA cases (entry date, dismissal terms, royalty triggers)?
5. If the court narrows claim construction, what design-around options typically preserve ANDA approval while avoiding infringement?

References (APA)

1. None provided in the prompt record.